References
- Darwin C. The expression of the emotions in man and animals. New York and London: D Appleton and Company, 1872.
- Robinson RG, Parikh RM, Lipsey JR, Starkstein SE, Price TR. Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. Am J Psychiatry 1993; 150: 286–293.
- Mukand J, Kaplan M, Senno RG, Bishop DS. Pathological crying and laughing: treatment with sertraline. Arch Phys Med Rehabil 1196; 77: 1309–1311.
- Nahas Z, Arlinghaus KA, Kotria KJ, Clearman RR, George MS. Rapid response of emotional incontinence to selective serotinin reuptake inhibitors. J Neuropsychiatry Clin Neurosci 1998; 10: 453–455.
- Newsome-Davis IC, Abrahams LH, Goldstein LH, Leigh N. The emotional lability questionnaire: a new measure of emotional lability in amyotrophic lateral sclerosis. J Neurological Sciences 1999; 169: 22–25.
- Moore SR, Gresham LS, Bromberg MB, Kasarkis EJ, Smith RA. A self-report measure of affective lability. J Neurol, Neurosurg and Psych 1997; 63: 89–93.
- Smith RA, Moore SR, Gresham LS, Manley PE, Licht JM. The treatment of affective lability in ALS patients with dextromethor- phan. Neurology 1995; 45: A330.
- Parvivzi P, Anderson SW, Martin CO, Damasio H, Damasio AR. Pathological laughter and crying/link to the cerebellum. Brain 2001; 124: 1708–1719.
- Zhang Y, Britto MR, Valderhaug KL, Wedlund PJ, Smith RA. Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. Clin Pharmac and Therap 1992; 51: 647–655.
- Musacchio JM, Klein M, Paturzo JJ. Effects of dextromethorphan site ligands and allosteric modifiers on the binding of (z)- [3H]3-(-3-hydroxyphenyl)-N-(1-propyl)piperidine. Mol Pharma- col 1989; 35(1): 1–5.